Please assess the completion status of the following clinical trial:

Trial Title: Yellow Fever Vaccine in Patients With Rheumatic Diseases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatic disease under low immunosuppression (hydroxychloroquine, sulfasalazine or methotrexate plus prednisone up to 7,5mg/day or leflunomide plus prednisone up to 7,5mg/day),~* Resident in high risk área for Yellow Fever~Exclusion Criteria:~* Active disease~* Primary immunodeficiency~* History of anaphylactic response to vaccine components or egg allergy~* Living outside the risk area~* Do not meet criteria for low immunosuppression~* History of previous immunization with the yellow fever vaccine~* History of live virus vaccine up to 4 weeks before~* Individuals who do not agree to participate in the study and/or whose parents do not agree to participate in the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Rheumatic diseases patients (Type: ACTIVE_COMPARATOR): Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
- Healthy controls (Type: ACTIVE_COMPARATOR): Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).